BRCA2 and neoplasm: BRCA2 siRNA + olaparib treatment decreased both the number (Figure 8B) and weight (Figure 8C) of tumors relative to BRCA2 siRNA or olaparib treatment alone (p<0.05), suggesting that combing BRCA2 reduction with PARP1 inhibition may be useful to decrease tumor burden.